30 completed, 5 recruiting, 3 terminated, 3 unknown. 14 Phase 1, 13 Not applicable, 10 Phase 2, 5 Early Phase 1, 5 Phase 4.
Follow exendin (9-39): new trials by email Literature Review of exendin (9-39) trials Research Report on exendin (9-39)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans Exendin 9-39, Saline - Genetic Predisposition, Type2diabetes | Phase 2 | Not yet recruiting | Mayo Clinic | 80 | 2026-10-01 | 2026-01-30 |
| Islet Function in Gestational Diabetes Exendin 9-39 - Gestational Diabetes Mellitus | Phase 1 | Recruiting | Mayo Clinic | 90 | 2026-09-01 | 2026-09-08 |
| The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 Diabetes exendin(9-39)amide, Saline (0.9% NaCl) - Type 1 Diabetes | Not applicable | Completed | Asger Lund, MD | 12 | 2026-01-23 | 2026-04-29 |
| The Role of Islet GLP-1 in the Pathogenesis of Prediabetes Exendin 9-39, Saline - PreDiabetes | Phase 2 | Recruiting | Mayo Clinic | 60 | 2025-11-01 | 2025-12-15 |
| Avexitide for Treatment of Post-Bariatric Hypoglycemia Avexitide, Placebo - Post Bariatric Hypoglycemia | Phase 3 | Active not recruiting | Amylyx Pharmaceuticals Inc. | 75 | 2025-04-29 | 2026-08-24 |
| The Underlying Mechanisms Regarding the Effect of Glucagon on the Kidneys Will be Investigated in Healthy Males. Glucagon, Placebo, Glucagon and exendin 9-39 - Kidney Diseases | Not applicable | Unknown | Ali Asmar | 10 | 2024-02-20 | 2024-07-12 |
| Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia Avexitide - Acquired Hyperinsulinemic Hypoglycemia | Phase 2 | Completed | Dr. Tracey McLaughlin, MD | 25 | 2021-06-21 | 2023-06-09 |
| Glucagon Regulation of Glucose Metabolism Glucagon - Insulin Secretion | Phase 1 | Completed | David D'Alessio, M.D. | 19 | 2019-09-24 | 2021-05-14 |
| Regulation of Insulin Secretion by the GLP-1 Receptor Exendin (9-39), Dexamethasone, Hyperglycemic Clamp - Insulin Secretion | Phase 4 | Terminated | VA Office of Research and Development | 6 | 2018-07-01 | 2024-12-12 |
| Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia exendin 9-39, Placebo - Postbariatric Hypoglycemia | Phase 2 | Completed | Eiger BioPharmaceuticals | 18 | 2018-03-19 | 2022-07-18 |
| Gastrectomy, Eating Behaviour and GLP-1 Exendin 9-39, Placebo - Gastric Cancer, Dumping Syndrome | Not applicable | Completed | Cambridge University Hospitals NHS Foundation Trust | 5 | 2017-08-10 | 2019-08-29 |
| Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines Acarbose, Placebo Oral Tablet, Exendin (9-39) - Glucose Metabolism Disorders | Not applicable | Completed | University Hospital, Gentofte, Copenhagen | 15 | 2017-08-01 | 2020-03-26 |
| The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D Placebo Oral Tablet, Metformin, Saline - Glucose Metabolism Disorders | Not applicable | Completed | University Hospital, Gentofte, Copenhagen | 15 | 2017-07-01 | 2018-07-09 |
| Cardiovascular Effects of GLP-1 Receptor Activation Liraglutide, Sitagliptin, hypocaloric diet - Obesity, PreDiabetes | Phase 4 | Completed | Vanderbilt University Medical Center | 329 | 2017-05-01 | 2022-10-18 |
| Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist GIP-A, GLP-1 receptor antagonist Exendin[9-39], Placebo - Glucose Metabolism Disorders | Not applicable | Completed | University Hospital, Gentofte, Copenhagen | 18 | 2017-03-01 | 2017-11-01 |
| Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4) GIP-A, Placebo, GLP-1 receptor antagonist Exendin[9-39] - Glucose Metabolism Disorders | Not applicable | Completed | University Hospital, Gentofte, Copenhagen | 12 | 2016-10-01 | 2019-06-04 |
| Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia Lyo avexitide, Liq avexitide - Post Bariatric Hypoglycemia | Phase 2 | Completed | Tracey McLaughlin | 19 | 2016-05-01 | 2020-11-13 |
| Mechanisms Underlying Predictors of Success From Obesity Surgery Exendin 9-39 and Sitagliptin, Placebo - Obesity | Phase 2 | Withdrawn | Icahn School of Medicine at Mount Sinai | 2016-01-01 | 2022-11-15 | |
| The Effects of Bariatric Surgeries on Glucose Metabolism Exendin-(9-39), Atropine - Post Bariatric Surgery, Gastric Bypass | Early Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 200 | 2015-07-01 | 2025-09-09 |
| Glucagon Like Peptide-1 in Remote Ischemic Conditioning Remote conditioning, Exendin 9-39 - Healthy Volunteers | Not applicable | Completed | Karolinska Institutet | 12 | 2015-05-01 | 2018-03-07 |
Showing 20 of 46. Sign in to see all of them.
Hypoglycemia (11) · Diabetes Mellitus, Type 2 (6) · Glucose Metabolism Disorders (6) · Insulin Resistance (5) · Congenital Hyperinsulinism (4) · Obesity (4) · Diabetes Mellitus (3) · Glucose Intolerance (3) · Hyperinsulinism (3) · Prediabetic State (2) · Diabetes Mellitus, Type 1 (1) · Diabetes, Gestational (1) · Dumping Syndrome (1) · Dyspepsia (1) · Genetic Predisposition to Disease (1)
Ludwig-Maximilians - University of Munich (5) · Diva De Leon (4) · Mayo Clinic (4) · University Hospital, Gentofte, Copenhagen (4) · The University of Texas Health Science Center at San Antonio (3) · Tracey McLaughlin (3) · Amylyx Pharmaceuticals Inc. (2) · David Dalessio (2) · Adrian Vella (1) · Ali Asmar (1) · Asger Lund, MD (1) · Blandine Laferrere (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Carl T. Hayden VA Medical Center (1) · David D'Alessio, M.D. (1)
United States (30) · Denmark (7) · Germany (6) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Joerg Schirra, MD (4) · David D'Alessio, MD (3) · Filip K Knop, MD, PhD (3) · Adrian Vella, MD (2) · Marilyn Tan, MD (2) · Marzieh Salehi, MD, MS (2) · Adil Bharucha, MBBS, MD (1) · Adrian Vella, M.D. (1) · Ali Asmar, MD (1) · Aoife Egan, MB, BCh, PhD (1) · Blandine Laferrere, MD (1) · Christoph Beglinger, MD (1) · Colleen Craig, M.D. (1) · Colleen Craig, MD (1)
PMID 32730920, PMID 22721966, PMID 22855730, PMID 24296715, PMID 24315990, PMID 24965303, PMID 25049134, PMID 27207543, PMID 27975209, PMID 29478970, PMID 30065032, PMID 30358871, PMID 30523032, PMID 30626611, PMID 32077470, PMID 32250530, PMID 33616643, PMID 34857533, PMID 35416981, PMID 39049802, PMID 42744082, PMID 8550855, PMID 9525985
F32DK113747 (1), K23HL119602 (1), P01DK068055 (1), R01DK082396 (1), R01DK098056 (1), R01DK101991 (1), R01DK105379 (1), R01DK108643 (1), R01DK148528 (1), R03DK078535 (1), R03DK083502 (1), UL1RR024150 (1)